Table 2 Comparison of the clinical characteristics of patients with and without non-fibrosis.

From: TET3 as a non-invasive screening tool for the detection of fibrosis in patients with chronic liver disease

 

Non-fibrosis (n = 38)

Fibrosis (n = 102)

Average age, years (range)

41.92(15,64)

46.62(20,86)

Gender

Male(%)

17(44.74)

62(60.78)

Female(%)

21(55.26)

40(39.22)

Serum ALT level (U/L) (Median, range)

45.20(19.45,235.10)

25.50(16.48,41.50)a

Serum AST leve (U/L) (Median, range)

42.05(24.53,90.40)

24.80(20.00,35.03)a

APRI score (Median, range)

0.71(0.36,1.23)

0.46(0.31,0.70)a

PLT(× 109/L) Mean ± SD

201.33 ± 60.89

167.88 ± 55.07a

HBsAg (> 0.4 IU/mL)

Negative (%)

18(47.34)

13(12.75)

Positive (%)

20(52.63)

89(87.25)a

FIB-4 Index (Median, range)

1.33(0.83,1.83)

1.49(0.96,2.26)

TET3 ng/mL (Median, range)

117.73(71.37,174.36)

648.66(154.62,1040.71)a

  1. aP < 0.05 versus Non-fibrosis.
  2. ALT, alanine aminotransferase; AST, aspartate aminotransferase; FIB-4, fibrosis-4; APRI, AST to platelet ratio Index; PLT, platelet count; HBsAg, Hepatitis B surface antigen; TET3, Ten-eleven translocation protein 3.
Back to article page